Cochrane · systematic review · CD000059
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A, Al‐Haj Haasan, N, Li, C, et al. · Cochrane Database of Systematic Reviews · 2009 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 7.1%Very low 0 · 0%Low 0 · 0%Moderate 13 · 92.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
CLOZAPINE versus TYPICAL ANTIPSYCHOTICS ‐ OVERALL for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse ‐ short term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 0.62 [0.45, 0.84] | 19 studies · 1303 participants | Moderate Downgraded: risk of bias |
Relapse ‐ long term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 0.22 [0.14, 0.34] | 4 studies · 578 participants | Moderate Downgraded: risk of bias |
Global impression: 1. Not clinically improved ‐ short term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 0.72 [0.66, 0.79] | 14 studies · 1119 participants | Moderate Downgraded: risk of bias |
Unable to work CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 0.87 [0.75, 1] | 4 studies · 416 participants | Moderate Downgraded: risk of bias |
Adverse effects: 1. Blood problems ‐ decreased white cell count CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 7.09 [1.96, 25.62] | 13 studies · 1031 participants | Moderate Downgraded: risk of bias |
Adverse effects: 4. Salivation ‐ too much CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 2.25 [1.96, 2.58] | 17 studies · 1479 participants | Moderate Downgraded: risk of bias |
Adverse effects: 5a. Weight gain CLOZAPINE vs TYPICAL ANTIPSYCHOTICS ‐ OVERALL | RR 1.28 [1.07, 1.53] | 5 studies · 590 participants | Moderate Downgraded: risk of bias |
CLOZAPINE versus TYPICAL ANTIPSYCHOTICS for people with schizophrenia whose illness has proved resistant to treatment
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse ‐ short term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 1.04 [0.61, 1.78] | 4 studies · 396 participants | Moderate Downgraded: risk of bias |
Relapse ‐ long term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 0.17 [0.1, 0.3] | 1 study · 423 participants | Moderate Downgraded: risk of bias |
Global impression: 1. Not clinically improved ‐ short term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 0.71 [0.64, 0.79] | 4 studies · 370 participants | Moderate Downgraded: risk of bias |
Global impression: 1. Not clinically improved ‐ long term CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 0.83 [0.76, 0.91] | 2 studies · 648 participants | Moderate Downgraded: risk of bias |
Adverse effects 1. Blood problems CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 1.9 [0.97, 3.71] | 5 studies · 827 participants | Ungraded |
Adverse effects 4. Salivation ‐ too much CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 2.01 [1.74, 2.32] | 5 studies · 827 participants | Moderate Downgraded: risk of bias |
Adverse effects 5. Weight gain CLOZAPINE vs TYPICAL ANTIPSYCHOTICS | RR 1.33 [1.11, 1.59] | 3 studies · 484 participants | Moderate Downgraded: risk of bias |